ABLE Financial Group LLC Buys 55 Shares of Eli Lilly and Company (NYSE:LLY)

ABLE Financial Group LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 6.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 958 shares of the company’s stock after purchasing an additional 55 shares during the period. ABLE Financial Group LLC’s holdings in Eli Lilly and Company were worth $867,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the stock. WealthShield Partners LLC grew its holdings in Eli Lilly and Company by 9.8% during the 2nd quarter. WealthShield Partners LLC now owns 3,804 shares of the company’s stock worth $3,444,000 after acquiring an additional 339 shares during the period. Checchi Capital Advisers LLC grew its holdings in Eli Lilly and Company by 1.0% during the 2nd quarter. Checchi Capital Advisers LLC now owns 10,977 shares of the company’s stock worth $9,938,000 after acquiring an additional 111 shares during the period. Harbour Investments Inc. grew its holdings in Eli Lilly and Company by 3.0% during the 2nd quarter. Harbour Investments Inc. now owns 7,995 shares of the company’s stock worth $7,239,000 after acquiring an additional 236 shares during the period. Bensler LLC grew its holdings in Eli Lilly and Company by 8.1% during the 2nd quarter. Bensler LLC now owns 13,355 shares of the company’s stock worth $12,091,000 after acquiring an additional 998 shares during the period. Finally, Atomi Financial Group Inc. grew its holdings in Eli Lilly and Company by 11.6% during the 2nd quarter. Atomi Financial Group Inc. now owns 5,283 shares of the company’s stock worth $4,783,000 after acquiring an additional 550 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $5.54 on Wednesday, reaching $948.94. The stock had a trading volume of 1,679,523 shares, compared to its average volume of 3,081,131. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53. The firm has a market capitalization of $901.88 billion, a price-to-earnings ratio of 140.80, a P/E/G ratio of 1.81 and a beta of 0.41. The firm’s 50-day moving average is $887.63 and its two-hundred day moving average is $816.72. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the company from $725.00 to $1,025.00 in a report on Monday, August 12th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, August 19th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $961.76.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 22,206 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $822.11, for a total value of $18,255,774.66. Following the transaction, the insider now owns 98,401,604 shares in the company, valued at approximately $80,896,942,664.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 22,206 shares of the stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $822.11, for a total transaction of $18,255,774.66. Following the transaction, the insider now owns 98,401,604 shares in the company, valued at approximately $80,896,942,664.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,120,089 shares of company stock worth $990,278,343. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.